$LAB
STANDARD BIOTOOLS INC. Stock $lab

$lab Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024023845 Filed on March 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$45.54M	$28.19M	$106.3M
YoY Change	81.3%	4.32%	8.57%
Cost Of Revenue	$21.35M	$14.83M	$55.89M
YoY Change	64.31%	-6.45%	-8.22%
Gross Profit	$24.19M	$13.36M	$50.45M
YoY Change	99.51%	19.61%	36.16%
Gross Profit Margin	53.11%	47.39%	47.44%
Selling, General & Admin	$46.94M	$21.35M	$87.54M
YoY Change	110.43%	-10.66%	-23.72%
% of Gross Profit	194.08%	159.87%	173.52%
Research & Development	$15.98M	$6.909M	$25.95M
YoY Change	149.34%	-17.52%	-32.6%
% of Gross Profit	66.07%	51.73%	51.43%
Depreciation & Amortization	$5.194M	$3.906M	$12.67M
YoY Change	41.84%	7.93%	103.65%
% of Gross Profit	21.47%	29.24%	25.12%
Operating Expenses	$84.37M	$28.26M	$127.1M
YoY Change	102.27%	-12.44%	-40.67%
Operating Profit	-$60.18M	-$14.91M	-$76.60M
YoY Change	262.7%	-29.4%	-34.08%
Interest Expense	$5.174M	-$1.098M	$4.567M
YoY Change	363.21%	-7.73%	5.45%
% of Operating Profit
Other Income/Expense, Net	-$2.234M	$2.546M	$6.963M
YoY Change	-297.7%	66.73%	454.82%
Pretax Income	-$32.03M	-$19.94M	-$74.20M
YoY Change	93.18%	-4.03%	-61.54%
Income Tax	$100.0K	-$162.0K	$452.0K
% Of Pretax Income
Net Earnings	-$32.16M	-$19.78M	-$74.66M
YoY Change	90.92%	-5.13%	-60.73%
Net Earnings / Revenue	-70.61%	-70.16%	-70.21%
Basic Earnings Per Share	-$0.27		-$0.94
Diluted Earnings Per Share	-$0.27	-$0.25	-$0.94
COMMON SHARES
Basic Shares Outstanding	290.1M	79.40M	79.16M
Diluted Shares Outstanding	294.1M		79.16M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$462.3M	$114.9M	$114.9M
YoY Change	199.14%	-30.7%	-30.7%
Cash & Equivalents	$287.1M	$51.70M	$51.70M
Short-Term Investments	$175.2M	$63.19M	$63.19M
Other Short-Term Assets	$8.912M	$3.127M	$3.127M
YoY Change	164.14%	-26.91%	-26.91%
Inventory	$40.36M	$20.53M	$20.53M
Prepaid Expenses
Receivables	$36.01M	$19.66M	$19.66M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$547.6M	$158.2M	$158.2M
YoY Change	180.91%	-24.23%	-24.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$44.79M	$24.19M	$54.85M
YoY Change	79.13%	-5.71%	-7.87%
Goodwill	$106.3M	$106.3M
YoY Change	-0.02%	0.06%
Intangibles	$24.79M	$1.400M
YoY Change	153.0%	-88.89%
Long-Term Investments
YoY Change
Other Assets	$3.673M	$2.285M	$2.278M
YoY Change	37.82%	-26.5%	-26.73%
Total Long-Term Assets	$230.1M	$164.9M	$164.9M
YoY Change	30.2%	-9.17%	-9.17%
TOTAL ASSETS
Total Short-Term Assets	$547.6M	$158.2M	$158.2M
Total Long-Term Assets	$230.1M	$164.9M	$164.9M
Total Assets	$777.7M	$323.1M	$323.1M
YoY Change	109.24%	-17.23%	-17.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.14M	$9.236M	$9.236M
YoY Change	115.11%	16.7%	16.7%
Accrued Expenses	$30.43M	$9.152M	$24.90M
YoY Change	342.43%	48.21%	30.96%
Deferred Revenue	$13.91M	$11.61M
YoY Change	19.51%	7.55%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$54.66M	$59.53M	$59.53M
YoY Change	1539.84%	2757.9%	2757.9%
Total Short-Term Liabilities	$121.6M	$109.3M	$109.3M
YoY Change	177.6%	151.66%	151.66%
LONG-TERM LIABILITIES
Long-Term Debt	$299.0K	$3.983M	$3.983M
YoY Change	-99.52%	-93.66%	-93.66%
Other Long-Term Liabilities	$2.820M	$1.065M	$45.71M
YoY Change	412.73%	10.82%	-14.1%
Total Long-Term Liabilities	$2.820M	$1.065M	$49.70M
YoY Change	412.73%	10.82%	-57.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$121.6M	$109.3M	$109.3M
Total Long-Term Liabilities	$2.820M	$1.065M	$49.70M
Total Liabilities	$200.4M	$159.9M	$159.9M
YoY Change	27.16%	-0.41%	-0.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.079B	-$1.001B
YoY Change	14.42%	8.06%
Common Stock	$387.0K	$83.00K
YoY Change	383.75%	3.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$577.3M	-$148.1M	$163.2M
YoY Change
Total Liabilities & Shareholders Equity	$777.7M	$323.1M	$323.1M
YoY Change	109.24%	-17.23%	-17.23%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$32.16M	-$19.78M	-$74.66M
YoY Change	90.92%	-5.13%	-60.73%
Depreciation, Depletion And Amortization	$5.194M	$3.906M	$12.67M
YoY Change	41.84%	7.93%	103.65%
Cash From Operating Activities	-$62.48M	-$14.06M	-$43.29M
YoY Change	636.31%	-26.69%	-51.56%
INVESTING ACTIVITIES
Capital Expenditures	$781.0K	$78.00K	$2.831M
YoY Change	-22.67%	-89.67%	-25.99%
Acquisitions
YoY Change
Other Investing Activities	$318.9M	-$13.04M	$23.07M
YoY Change	621.98%	-131.8%	-127.36%
Cash From Investing Activities	$318.1M	-$13.12M	$20.24M
YoY Change	637.07%	-132.59%	-122.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$5.400M
YoY Change			800.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-19.73M	-1.003M	-6.809M
YoY Change	671.42%	271.48%	-102.95%
NET CHANGE
Cash From Operating Activities	-62.48M	-14.06M	-43.29M
Cash From Investing Activities	318.1M	-13.12M	20.24M
Cash From Financing Activities	-19.73M	-1.003M	-6.809M
Net Change In Cash	235.8M	-28.18M	-29.83M
YoY Change	633.94%	-235.52%	-156.43%
FREE CASH FLOW
Cash From Operating Activities	-$62.48M	-$14.06M	-$43.29M
Capital Expenditures	$781.0K	$78.00K	$2.831M
Free Cash Flow	-$63.26M	-$14.14M	-$46.12M
YoY Change	566.21%	-29.08%	-50.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001162194
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-34180
CY2023	dei	Entity Registrant Name EntityRegistrantName	STANDARD BIOTOOLS INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0513190
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2 Tower Place, Suite 2000
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco,
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2023	dei	City Area Code CityAreaCode	650
CY2023	dei	Local Phone Number LocalPhoneNumber	266-6000
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	LAB
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	132700000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	290117930
CY2023	dei	Auditor Firm AuditorFirmId	238
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2023	dei	Auditor Location AuditorLocation	San Jose, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51704000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81309000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	63191000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	84475000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	312000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	592000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19660000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17280000
CY2023Q4	us-gaap	Inventory Net InventoryNet	20533000
CY2022Q4	us-gaap	Inventory Net InventoryNet	21473000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3127000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4278000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	158215000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	208815000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24187000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25652000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	30663000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33883000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2285000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3109000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1400000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12600000
CY2023Q4	us-gaap	Goodwill Goodwill	106317000
CY2022Q4	us-gaap	Goodwill Goodwill	106251000
CY2023Q4	us-gaap	Assets Assets	323067000
CY2022Q4	us-gaap	Assets Assets	390310000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9236000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7914000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11867000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9153000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4323000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3682000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11607000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10792000
CY2023Q4	lab	Deferred Grant Revenue Current DeferredGrantRevenueCurrent	3612000
CY2022Q4	lab	Deferred Grant Revenue Current DeferredGrantRevenueCurrent	3644000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9152000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6175000
CY2023Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	5000000
CY2022Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	2083000
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	54530000
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	109327000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	43443000
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	569000
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	54615000
CY2023Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	3414000
CY2022Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	8194000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	841000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1055000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30374000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34081000
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3520000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3816000
CY2023Q4	lab	Deferred Grant Income Noncurrent DeferredGrantIncomeNoncurrent	10755000
CY2022Q4	lab	Deferred Grant Income Noncurrent DeferredGrantIncomeNoncurrent	14359000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1065000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	961000
CY2023Q4	us-gaap	Liabilities Liabilities	159865000
CY2022Q4	us-gaap	Liabilities Liabilities	160524000
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	256000
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	256000
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	256000
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	256000
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	256000
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	256000
CY2022Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	255559000
CY2023Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	255559000
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	311253000
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	311253000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	9744000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	9744000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	83364000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	79904000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	80232000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	79482000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	83000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	80000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	860816000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	847008000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2221000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1896000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1000752000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-926096000
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	3132000
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	422000
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	5977000
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	563000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-148051000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-81467000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	323067000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	390310000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	106340000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	97948000
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	55890000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	60897000
CY2023	us-gaap	Gross Profit GrossProfit	50450000
CY2022	us-gaap	Gross Profit GrossProfit	37051000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25948000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37382000
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	87541000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	102285000
CY2023	us-gaap	Restructuring Charges RestructuringCharges	7076000
CY2022	us-gaap	Restructuring Charges RestructuringCharges	9732000
CY2023	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	6485000
CY2022	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	3857000
CY2023	us-gaap	Operating Expenses OperatingExpenses	127050000
CY2022	us-gaap	Operating Expenses OperatingExpenses	153256000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-76600000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-116205000
CY2023	us-gaap	Interest Expense InterestExpense	4567000
CY2022	us-gaap	Interest Expense InterestExpense	4331000
CY2023	lab	Loss On Forward Sale Of Stock LossOnForwardSaleOfStock	0
CY2022	lab	Loss On Forward Sale Of Stock LossOnForwardSaleOfStock	60081000
CY2023	us-gaap	Debt Securities Gain Loss DebtSecuritiesGainLoss	0
CY2022	us-gaap	Debt Securities Gain Loss DebtSecuritiesGainLoss	-13719000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6963000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1408000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-74204000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-192928000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	452000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2830000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-74656000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-190098000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.94
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.94
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.43
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.43
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	79160000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	79160000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	78305000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78305000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-74656000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-190098000
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-849000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-487000
CY2023	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	524000
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-502000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-325000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-989000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-74981000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-191087000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	94596000
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-211000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	820000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	98000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14880000
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	563000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-190098000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-989000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-81467000
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-116000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	81000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	723000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13123000
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	5414000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-74656000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-325000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-148051000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-74656000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-190098000
CY2023	lab	Loss On Forward Sale Of Stock LossOnForwardSaleOfStock	0
CY2022	lab	Loss On Forward Sale Of Stock LossOnForwardSaleOfStock	60081000
CY2023	us-gaap	Debt Securities Gain Loss DebtSecuritiesGainLoss	0
CY2022	us-gaap	Debt Securities Gain Loss DebtSecuritiesGainLoss	-13719000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	13123000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	14880000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11200000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11528000
CY2023	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	3980000
CY2022	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	3499000
CY2023	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	1496000
CY2022	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	7874000
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	3526000
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	770000
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	830000
CY2023	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-987000
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	273000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2991000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1063000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4914000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8470000
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	801000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	309000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-960000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-33000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1618000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2776000
CY2023	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	3018000
CY2022	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	4113000
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	884000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3467000
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	3212000
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-5978000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-43287000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-89370000
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	94896000
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	137302000
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Other Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments	117964000
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Other Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments	53000000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2831000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3825000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	20237000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-88127000
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	25000000
CY2023	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0
CY2022	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	225000000
CY2023	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	2083000
CY2022	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	6838000
CY2023	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0
CY2022	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	12547000
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	5414000
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	563000
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	827000
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	917000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	139000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	211000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6809000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	230758000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-404000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-29825000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	52857000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82324000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29467000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52499000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82324000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	3819000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	3493000
CY2023	lab	Non Cash Right Of Use Assets And Lease Liabilities NonCashRightOfUseAssetsAndLeaseLiabilities	629000
CY2022	lab	Non Cash Right Of Use Assets And Lease Liabilities NonCashRightOfUseAssetsAndLeaseLiabilities	651000
CY2023	lab	Asset Retirement Obligations Incurred But Not Yet Paid AssetRetirementObligationsIncurredButNotYetPaid	758000
CY2022	lab	Asset Retirement Obligations Incurred But Not Yet Paid AssetRetirementObligationsIncurredButNotYetPaid	718000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, the current economic environment and on various other assumptions believed to be reasonable, which together form the basis for making judgments about the carrying values of assets and liabilities. These accounting matters included but were not limited to inventory and related reserves, the carrying value of goodwill and other long-lived assets, and the potential outcome of uncertain tax positions that have been recognized in the Company's financial statements or tax returns. The Company also uses significant judgment in determining the fair value of financial instruments, including debt and equity instruments. Actual results could differ materially from these estimates and could have a material adverse effect on the Company's consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	16740000
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	15752000
CY2023	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	75164000
CY2022	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	75164000
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	110880000
CY2023	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Business and Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents, short-term investments, and accounts receivable. The Company's cash, cash equivalents, and short-term investments may consist of deposits held with banks, money market funds, and other highly liquid investments that may at times exceed federally insured limits. Cash equivalents and short-term investments are financial instruments that potentially subject the Company to concentrations of risk. Under the Company's investment policy, the Company invests exclusively in securities issued by the U.S. government or U.S. government agencies, or in government money-market funds. The goals of the Company's investment policy, in order of priority, are to: preserve capital, meet liquidity needs, and optimize returns. For these reasons, management believes that the Company is not exposed to significant credit risk.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company generally does not require collateral to support credit sales. To reduce credit risk, the Company performs credit evaluations of its customers.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's products include components that are currently procured from a single source or a limited number of sources. The Company believes that other vendors would be able to provide similar components; however, the qualification of such vendors may require start-up time. In order to mitigate any adverse impacts from a disruption of supply, the Company attempts to maintain an adequate supply of critical limited-source components.</span></p>
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	109892000
CY2023Q4	lab	Number Of Additional Shares Issuable Under Make Whole Premium Maximum NumberOfAdditionalSharesIssuableUnderMakeWholePremiumMaximum	4741374
CY2023	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	2709703
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	3061000
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1112000
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	24060000
CY2023Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2023	us-gaap	Advertising Expense AdvertisingExpense	2000000
CY2022	us-gaap	Advertising Expense AdvertisingExpense	3900000
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassification</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain amounts in the consolidated financial statements have been reclassified from their original presentation to conform to current year presentation.</span></p>
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	106340000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	97948000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	106340000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	97948000
CY2023Q4	us-gaap	Noncurrent Assets NoncurrentAssets	54850000
CY2022Q4	us-gaap	Noncurrent Assets NoncurrentAssets	59535000
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	15100000
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	14600000
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	10600000
CY2023	lab	Contract With Customer Liability Increase From Cash Receipts ContractWithCustomerLiabilityIncreaseFromCashReceipts	11100000
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	13253000
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	6634000
CY2022Q4	us-gaap	Goodwill Goodwill	106251000
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	66000
CY2023Q4	us-gaap	Goodwill Goodwill	106317000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1407000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1407000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51704000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81309000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	795000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1015000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52499000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82324000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	800000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1000000
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	15539000
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	16866000
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	282000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	945000
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	11753000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	15245000
CY2023Q4	us-gaap	Inventory Gross InventoryGross	27574000
CY2022Q4	us-gaap	Inventory Gross InventoryGross	33056000
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	7041000
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	11583000
CY2023Q4	us-gaap	Inventory Net InventoryNet	20533000
CY2022Q4	us-gaap	Inventory Net InventoryNet	21473000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	57342000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	53069000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	35489000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	29029000
CY2023Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	2334000
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	1612000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24187000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25652000
CY2023	us-gaap	Depreciation Depreciation	3400000
CY2022	us-gaap	Depreciation Depreciation	2800000
CY2023Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	7337000
CY2022Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	1170000
CY2023Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	2711000
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	2795000
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	994000
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1174000
CY2023Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	825000
CY2022Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	4014000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11867000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9153000
CY2023Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	1010000
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	800000
CY2023Q4	lab	Accrued Interest Current AccruedInterestCurrent	295000
CY2022Q4	lab	Accrued Interest Current AccruedInterestCurrent	318000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	964000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	349000
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1230000
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1443000
CY2023Q4	lab	Uninvoiced Receipts Current UninvoicedReceiptsCurrent	1516000
CY2022Q4	lab	Uninvoiced Receipts Current UninvoicedReceiptsCurrent	1078000
CY2023Q4	lab	Accrued Warranties Current AccruedWarrantiesCurrent	2593000
CY2022Q4	lab	Accrued Warranties Current AccruedWarrantiesCurrent	678000
CY2023Q4	lab	Customer Advance Current CustomerAdvanceCurrent	447000
CY2022Q4	lab	Customer Advance Current CustomerAdvanceCurrent	577000
CY2023Q4	lab	Accrued Restructuring Current AccruedRestructuringCurrent	0
CY2022Q4	lab	Accrued Restructuring Current AccruedRestructuringCurrent	19000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1097000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	913000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9152000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6175000
CY2020Q3	lab	Research And Development Arrangement Contract To Perform For Others Maximum Contract Value ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumContractValue	34000000
CY2020Q3	lab	Research And Development Arrangement Contract To Perform For Others Capital Expenditures ResearchAndDevelopmentArrangementContractToPerformForOthersCapitalExpenditures	22200000
CY2023	lab	Research And Development Arrangement Contract To Perform For Others Depreciation Expense ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense	3600000
CY2022	lab	Research And Development Arrangement Contract To Perform For Others Depreciation Expense ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense	3500000
CY2023Q4	lab	Research And Development Arrangement Contract To Perform For Others Accumulated Depreciation Expenses ResearchAndDevelopmentArrangementContractToPerformForOthersAccumulatedDepreciationExpenses	7800000
CY2022Q4	lab	Research And Development Arrangement Contract To Perform For Others Accumulated Depreciation Expenses ResearchAndDevelopmentArrangementContractToPerformForOthersAccumulatedDepreciationExpenses	4200000
CY2023Q4	lab	Research And Development Arrangement Contract To Perform For Others Property And Equipment Net ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet	14400000
CY2022Q4	lab	Research And Development Arrangement Contract To Perform For Others Property And Equipment Net ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet	18000000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	63513000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	64892000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	5000000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2917000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	7917000
CY2023	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	497000
CY2023Q4	us-gaap	Line Of Credit LineOfCredit	8414000
CY2023Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2023	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2030-04-30
CY2023	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	contains an option to extend the lease
CY2023	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2023Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2023	us-gaap	Lessee Operating Lease Option To Terminate LesseeOperatingLeaseOptionToTerminate	along with termination options
CY2023	us-gaap	Lessee Operating Lease Existence Of Option To Terminate LesseeOperatingLeaseExistenceOfOptionToTerminate	true
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y10M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y9M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.118
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.118
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	11159000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	10917000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	3164000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	2930000
CY2023	us-gaap	Sublease Income SubleaseIncome	2679000
CY2022	us-gaap	Sublease Income SubleaseIncome	189000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	7931000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	7540000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8086000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	2877000
CY2023Q4	lab	Lessee Net Operating Lease Liability Payments Due Next Twelve Months LesseeNetOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5209000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	8135000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	2952000
CY2023Q4	lab	Lessee Net Operating Lease Liability Payments Due Year Two LesseeNetOperatingLeaseLiabilityPaymentsDueYearTwo	5183000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	7821000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	1381000
CY2023Q4	lab	Lessee Net Operating Lease Liability Payments Due Year Three LesseeNetOperatingLeaseLiabilityPaymentsDueYearThree	6440000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	7395000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	1430000
CY2023Q4	lab	Lessee Net Operating Lease Liability Payments Due Year Four LesseeNetOperatingLeaseLiabilityPaymentsDueYearFour	5965000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	7355000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Five Years LessorOperatingLeasePaymentsToBeReceivedFiveYears	1480000
CY2023Q4	lab	Lessee Net Operating Lease Liability Payments Due Year Five LesseeNetOperatingLeaseLiabilityPaymentsDueYearFive	5875000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	10225000
CY2023Q4	lab	Lessor Operating Lease Payment To Be Received After Year Five LessorOperatingLeasePaymentToBeReceivedAfterYearFive	2058000
CY2023Q4	lab	Lessee Net Operating Lease Liability Payments Due After Year Five LesseeNetOperatingLeaseLiabilityPaymentsDueAfterYearFive	8167000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	49017000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	12178000
CY2023Q4	lab	Lessee Net Operating Lease Liability Payments Due LesseeNetOperatingLeaseLiabilityPaymentsDue	36839000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	14320000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	34697000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4323000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30374000
CY2023Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	9700000
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	98554000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	22000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	98576000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	138871000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	502000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	138369000
CY2023Q4	us-gaap	Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss	0
CY2023	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Sell Before Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery	0
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2022Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	20000000
CY2023	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	2709703
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	5400000
CY2023	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	1.98
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6445000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7882000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.43
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y10M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	2609000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.57
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	44000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.84
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1153000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.84
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9294000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.62
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y6M
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	439000
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	3497000
CY2023Q4	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	3.98
CY2023	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term One ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTermOne	P8Y2M12D
CY2023Q4	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAggregateIntrinsicValue	78000
CY2023	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber	5797000
CY2023Q4	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice	3.4
CY2023	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageRemainingContractualTerm1	P8Y8M12D
CY2023Q4	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue	361000
CY2023Q4	us-gaap	Share Price SharePrice	2.21
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.971
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.918
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y8M12D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y3M18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.039
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.026
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.49
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.21
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13123000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14880000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-40587000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-174041000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-33617000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-18887000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-74204000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-192928000
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	197000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	87000
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	373000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	405000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	570000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	492000
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-118000
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-3322000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-118000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3322000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	452000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2830000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.013
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.008
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.081
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.008
CY2023	lab	Effective Income Tax Rate Reconciliation Net Operating Loss Carry Forward Percent EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryForwardPercent	0.055
CY2022	lab	Effective Income Tax Rate Reconciliation Net Operating Loss Carry Forward Percent EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryForwardPercent	0.228
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.219
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.171
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.002
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.002
CY2023	lab	Effective Income Tax Rate Reconciliation Unrecognized Tax Benefit EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefit	0
CY2022	lab	Effective Income Tax Rate Reconciliation Unrecognized Tax Benefit EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefit	0.009
CY2023	lab	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent	0
CY2022	lab	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent	0.003
CY2023	lab	Effective Income Tax Rate Reconciliation Nondeductible Expense Forward Sale Of Preferred Stock And Debt Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseForwardSaleOfPreferredStockAndDebtPercent	0
CY2022	lab	Effective Income Tax Rate Reconciliation Nondeductible Expense Forward Sale Of Preferred Stock And Debt Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseForwardSaleOfPreferredStockAndDebtPercent	0.08
CY2023	lab	Effective Income Tax Rate Reconciliation Research And Development Credit Percent EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCreditPercent	0
CY2022	lab	Effective Income Tax Rate Reconciliation Research And Development Credit Percent EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCreditPercent	0.052
CY2023	lab	Effective Income Tax Rate Transaction Cost EffectiveIncomeTaxRateTransactionCost	-0.015
CY2022	lab	Effective Income Tax Rate Transaction Cost EffectiveIncomeTaxRateTransactionCost	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.026
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.008
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.025
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.02
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.022
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.015
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	96242000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	85182000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	3152000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	3943000
CY2023Q4	lab	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	564000
CY2022Q4	lab	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	563000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5962000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3840000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	15463000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	14456000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1143000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2064000
CY2023Q4	lab	Deferred Tax Assets Operating Leases Right Of Use Liability DeferredTaxAssetsOperatingLeasesRightOfUseLiability	7782000
CY2022Q4	lab	Deferred Tax Assets Operating Leases Right Of Use Liability DeferredTaxAssetsOperatingLeasesRightOfUseLiability	8663000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	130308000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	118711000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	124124000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	107893000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	6184000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	10818000
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	54000
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	3913000
CY2023Q4	lab	Deferred Tax Liabilities Operating Leases Right Of Use Assets DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets	6836000
CY2022Q4	lab	Deferred Tax Liabilities Operating Leases Right Of Use Assets DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets	7729000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	6890000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	11642000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	706000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	824000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	841000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1055000
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	135000
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	231000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	706000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	824000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	124100000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	107900000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8515000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	154000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1697000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6972000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	105000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	138000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6939000
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	106340000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	97948000
CY2023	us-gaap	Gross Profit GrossProfit	50450000
CY2022	us-gaap	Gross Profit GrossProfit	37051000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12673000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12453000
CY2023	us-gaap	Restructuring Charges RestructuringCharges	7100000
CY2022	us-gaap	Restructuring Charges RestructuringCharges	9700000
CY2021Q4	us-gaap	Restructuring Reserve RestructuringReserve	0
CY2022	us-gaap	Restructuring Charges RestructuringCharges	9732000
CY2022	us-gaap	Payments For Restructuring PaymentsForRestructuring	5699000
CY2022Q4	us-gaap	Restructuring Reserve RestructuringReserve	4033000
CY2023	us-gaap	Restructuring Charges RestructuringCharges	7076000
CY2023	us-gaap	Payments For Restructuring PaymentsForRestructuring	10284000
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	825000
CY2023	us-gaap	Restructuring Charges RestructuringCharges	7076000
CY2022	us-gaap	Restructuring Charges RestructuringCharges	9732000
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2019	lab	Defined Contribution Plan Employer Matching Contribution Maximum Annual Match Per Employee Amount DefinedContributionPlanEmployerMatchingContributionMaximumAnnualMatchPerEmployeeAmount	3000
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	500000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	600000

Files In Submission

Name	View Source	Status
0000950170-24-023845-index-headers.html	Edgar Link	pending
0000950170-24-023845-index.html	Edgar Link	pending
0000950170-24-023845.txt	Edgar Link	pending
0000950170-24-023845-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img186398206_0.jpg	Edgar Link	pending
img186398206_1.jpg	Edgar Link	pending
lab-20231231.htm	Edgar Link	pending
lab-20231231.xsd	Edgar Link	pending
lab-ex10_2.htm	Edgar Link	pending
lab-ex10_96.htm	Edgar Link	pending
lab-ex21_1.htm	Edgar Link	pending
lab-ex23_1.htm	Edgar Link	pending
lab-ex31_1.htm	Edgar Link	pending
lab-ex31_2.htm	Edgar Link	pending
lab-ex32_1.htm	Edgar Link	pending
lab-ex32_2.htm	Edgar Link	pending
lab-ex4_2.htm	Edgar Link	pending
lab-ex97_1.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
lab-20231231_htm.xml	Edgar Link	completed
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LAB
STANDARD BIOTOOLS INC. Stock $lab

2024 Q1 Form 10-K Financial Statement

#000095017024023845 Filed on March 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LAB STANDARD BIOTOOLS INC. Stock $lab

2024 Q1 Form 10-K Financial Statement

#000095017024023845 Filed on March 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LAB
STANDARD BIOTOOLS INC. Stock $lab